文献速递腹部技术与安全MR

双表型原发性肝癌的影像-病理对照:2019 WHO分类变化及其对肝脏MRI LI-RADS分类的影响

Radio-pathologic correlation of biphenotypic primary liver cancer (combined hepatocellular cholangiocarcinoma): changes in the 2019 WHO classification and impact on LI-RADS classification at liver MRI.
PubMed 文献 · Eur Radiol · 2021-05-26

回顾性纳入209例按2010 WHO分类病理证实的双表型原发性肝癌患者,分析2019 WHO分类重新诊断的比例及对Gd-EOB-MRI LI-RADS分类的影响。2019分类下84.7%仍为双表型,12.0%改为HCC,3.3%改为CCA;LI-RADS分类在两种分类间无显著差异,HCC成分比例是LI-RADS分类的唯一独立因素。

要点

  • 2010 WHO分类的双表型PLC中约15%按2019 WHO分类改诊断为HCC或CCA。
  • 2019 WHO分类的双表型PLC中43.5%为LR-M、35.5%为LR-5、11.9%为LR-4。
  • HCC成分比例是LI-RADS分类的独立影响因素。

诊断标准与关键数值

  • 2010 WHO分类的209例双表型PLC中,2019 WHO分类重新诊断为双表型PLC 177例(84.7%)、HCC 25例(12.0%)、CCA 7例(3.3%)。
  • 2019 WHO分类的177例双表型PLC中,LI-RADS分类为LR-M 77例(43.5%)、LR-4 21例(11.9%)、LR-5 63例(35.5%)。
  • 2010与2019 WHO分类间LR-5和LR-M比例无显著差异(p=0.941)。
  • HCC成分比例是LI-RADS分类的唯一独立因素(调整OR=1.02,p<0.001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To explain the new changes in pathologic diagnoses of biphenotypic primary liver cancer (PLC) according to the updated 2019 World Health Organization (WHO) classification and how it impacts Liver Imaging Reporting and Data System (LI-RADS) classification using gadoxetic acid-enhanced MRI (Gd-EOB-MRI).

METHODS: We retrospectively included 209 patients with pathologically proven biphenotypic PLCs according to the 2010 WHO classification who had undergone preoperative Gd-EOB-MRI between January 2009 and December 2018. Imaging analysis including LI-RADS classification and pathologic review including the proportion of tumor components were performed. Frequencies of each diagnosis and subtype according to the 2010 and 2019 WHO classifications were compared, and changes in LI-RADS classification were evaluated. Univariable and multivariable analysis were performed to determine significant tumor component for LI-RADS classification.

RESULTS: Of the 209 biphenotypic PLCs of the 2010 WHO classification, 177 (84.7%) were diagnosed as bipheonotypic PLCs, 25 (12.0%) as hepatocellular carcinomas (HCCs), and 7 (3.3%) as cholangiocarcinomas (CCAs) using the 2019 WHO classification. Of the 177 biphenotypic PLCs, LR-M, LR-4, and LR-5 were assigned in 77 (43.5%), 21 (11.9%), and 63 (35.5%), respectively. There were no significant differences in the proportion of LR-5 and LR-M categories between the WHO 2010 and 2019 classifications (p = 0.941). Proportion of HCC component was the only independent factor for LI-RADS classification (adjusted odds ratio, 1.02; p < 0.001).

CONCLUSION: According to the 2019 WHO classification, 15% of biphenotypic PLCs from the 2010 WHO classification were re-diagnosed as HCCs or CCAs, and a substantial proportion of biphenotypic PLCs of the 2019 WHO classification could be categorized as LR-4 or LR-5 on Gd-EOB-MRI.

KEY POINTS: • Among 209 diagnosed biphenotypic PLCs according to the 2010 WHO classification, 177 (84.7%) lesions were reclassified as bipheonotypic PLCs, 25 (12.0%) as HCCs, and 7 (3.3%) as CCAs using the 2019 WHO classification. • Of the 177 biphenotypic PLCs at the 2019 WHO classification, LR-M, LR-4, and LR-5 were assigned in 77 (43.5%), 21 (11.9%), and 63 (35.5%), respectively. • LI-RADS classification relied on the proportion of HCC component (adjusted odds ratio,1.02; p < 0.001).

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Choi SH, Jeon SK, Lee SS, et al. Radio-pathologic correlation of biphenotypic primary liver cancer (combined hepatocellular cholangiocarcinoma): changes in the 2019 WHO classification and impact on LI-RADS classification at liver MRI. Eur Radiol. 2021. PMID: 34037829. doi:10.1007/s00330-021-07984-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。